Drug maker OBI Pharma Inc (台灣浩鼎) yesterday said that it will start generating revenue this year, driven by the planned launch of its DIFCID antibiotic in Taiwan by the end of the second quarter.
The company has failed to post revenue since 2011, before its started trading its shares on the Emerging Stock Market in 2012.
“We are currently finalizing talks with the National Health Insurance Administration concerning drug prices, as well as with our suppliers regarding materials prices,” general manager Amy Huang (黃秀美) said.
However, Huang said that the market for DIFCID in Taiwan is small because antibiotics are not overused in the nation and it is not in need of new kinds of antibiotics.
The company could continue its loss-making streak this year, since it is expected to spend between NT$600 million and NT$700 million (US$19.77 million and US$49 million) on research and development. OBI Pharma said that most of the amount will be used to finance clinical trials for its drugs.
In the first half of last year, the company spent NT$177.82 million on research and development, according to its stock exchange filing.
Over the same period, OBI Pharma reported NT$202.47 million in losses, an increase from the NT$101.03 million in losses it posted a year ago that was the result of more spending on research and development, its filing showed.
The construction of Amaran Biotechnology Inc’s (潤雅生技) new factory in the Hsinchu Biomedical Science Park (新竹生醫園區) will be operational at the end of this year after the factory receives Good Manufacturing Practice its (GMP) certificate from the government, Huang said, adding that the factory will make botox for OBI Pharma.
According to Huang, the company will complete data collection for phase-three clinical trails for OBI-822, which is used to treat breast cancer, in Taiwan by the end of June.
The company plans to file for a permit to sell OBI-822 in Taiwan in 2016 and in the US in 2018, it said.
The firm is to launch the cancer drug in the US, Taiwan and China on its own, but is seeking partners to sell the medication in Europe and Japan, it said.
OBI Pharma also acquired a new monoclonal antibody to treat cancer last year from Academia Sinica, Huang said, adding that the drug is in the pre-clinical trial stage.
It also has plans to shift to the GRETAI Securities Market by the end of this year.
OBI Pharma stock fell 1.51 percent to NT$227.94 yesterday on the Emerging Stock Market.
Netherlands-based semiconductor equipment supplier ASML Holding NV yesterday said that it is planning to hire an additional 1,000 people in Taiwan this year in response to growing demand from clients. ASML had previously planned to recruit 600 people this year, but that the plan has been adjusted upward, ASML vice president and ASML Taiwan general manager Grace Wang (汪佳慧) told reporters. ASML has a workforce of more than 4,500 in Taiwan, accounting for about 10 percent of its global total, Wang said. This year’s recruitment campaign would focus on adding people in the customer support, manufacturing and supply chain domains to assist ASML
Starlux Airlines Co (星宇航空) today unveiled a long-haul network expansion plan at a shareholders’ meeting in Taipei, including direct flights to Barcelona, Spain, and Zurich, Switzerland, as well as a service connecting Taipei, Sydney and New Zealand. Starlux is to become the first Taiwanese carrier to offer non-stop services to the two European cities, while the inaugural oceanic route is expected to expand transit opportunities within the Australia-New Zealand market, Starlux said. Flight services to Chicago, Dallas, Washington and New York are under evaluation, the airline added. Prior to the shareholders’ meeting, the airline earlier this year announced that it would be
UNDER MICROSCOPE: Taiwan detained three people who allegedly conspired to buy servers in Taiwan and export them using fraudulent documentation, prosecutors said Nvidia Corp chief executive officer Jensen Huang (黃仁勳) on Saturday urged Super Micro Computer Inc to tighten up on compliance after Taiwan detained three people this week for allegedly making fraudulent declarations about artificial intelligence (AI) servers made by its US partner. The development marked the nation’s first crackdown on semiconductor smuggling, which grew after the US slapped restrictions on exports of high-end chips such as Nvidia AI accelerators to China. Nvidia is “rigorous” in explaining regulations to all of its partners, Huang told reporters after arriving in Taipei. “Ultimately Super Micro has to run their own company,” he said in response to
Nvidia Corp yesterday announced that CEO Jensen Huang (黃仁勳) would attend an employee meeting in Taipei tomorrow to celebrate the launch of the company’s Taiwan headquarters project. Huang would attend a gathering at the site of Nvidia’s planned headquarters in Beitou Shilin Technology Park (北投士林科技園區), the company said in a statement. After arriving in Taiwan on Saturday last week, Huang told reporters that he plans to meet with Quanta Computer Inc (廣達) chairman Barry Lam (林百里) and Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) chairman C.C. Wei (魏哲家), and would attend the groundbreaking ceremony for Nvidia’s Taiwan headquarters tomorrow. Nvidia has not yet applied
RSS